Report cover image

Meningococcal Vaccines Market (Type: Polysaccharide, Conjugate Vaccines, Combination Vaccines, Men B Vaccine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Publisher Transparency Market Research Pvt. Ltd.
Published May 27, 2022
Length 189 Pages
SKU # TNPR17326567

Description

Meningococcal Vaccines Market (Type: Polysaccharide, Conjugate Vaccines, Combination Vaccines, Men B Vaccine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Companies Mentioned

Sanofi SA
Novartis International
GlaxoSmithKline plc
Pfizer Inc.
Nuron Biotech.
JN-International Medical Corporation.
Serum Institute of India Ltd
Baxter International

Countries

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Forecast Year (first) - 2022

Forecast Year (last) - 2031

Forecast Year ( first)  Value - 4.2

Forecast Year (last) Value - 9.2

CAGR % - 0.094

Currency - US$ Bn

Table of Contents

189 Pages
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Meningococcal Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Region/globally
5.3. Covid-19 Impact analysis
6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
6.3.1. Polysaccharide
6.3.1.1. Menomune
6.3.1.2. Mencevax
6.3.1.3. NmVac4
6.3.1.4. Others
6.3.2. Conjugate Vaccines
6.3.2.1. Menactra
6.3.2.2. Menveo
6.3.2.3. NeisVac-C
6.3.2.4. Nimenrix
6.3.2.5. Others
6.3.3. Combination Vaccines
6.3.3.1. MenHibrix
6.3.3.2. Menitorix
6.3.4. Men B Vaccines
6.3.4.1. Bexsero
6.3.4.2. Trumenba
6.4. Global Meningococcal Vaccines Market Attractiveness, by Type
7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others (online pharmacies, drug stores)
7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user
8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Meningococcal Vaccines Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region
9. North America Meningococcal Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
9.2.1. Polysaccharide
9.2.1.1. Menomune
9.2.1.2. Mencevax
9.2.1.3. NmVac4
9.2.1.4. Others
9.2.2. Conjugate Vaccines
9.2.2.1. Menactra
9.2.2.2. Menveo
9.2.2.3. NeisVac-C
9.2.2.4. Nimenrix
9.2.2.5. Others
9.2.3. Combination Vaccines
9.2.3.1. MenHibrix
9.2.3.2. Menitorix
9.2.4. Men B Vaccines
9.2.4.1. Bexsero
9.2.4.2. Trumenba
9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Others (online pharmacies, drug stores)
9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021–2031
9.4.1. U.S.
9.4.2. Canada
9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By End-user
9.5.3. By Country
10. Europe Meningococcal Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
10.2.1. Polysaccharide
10.2.1.1. Menomune
10.2.1.2. Mencevax
10.2.1.3. NmVac4
10.2.1.4. Others
10.2.2. Conjugate Vaccines
10.2.2.1. Menactra
10.2.2.2. Menveo
10.2.2.3. NeisVac-C
10.2.2.4. Nimenrix
10.2.2.5. Others
10.2.3. Combination Vaccines
10.2.3.1. MenHibrix
10.2.3.2. Menitorix
10.2.4. Men B Vaccines
10.2.4.1. Bexsero
10.2.4.2. Trumenba
10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Others (online pharmacies, drug stores)
10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
11.2.1. Polysaccharide
11.2.1.1. Menomune
11.2.1.2. Mencevax
11.2.1.3. NmVac4
11.2.1.4. Others
11.2.2. Conjugate Vaccines
11.2.2.1. Menactra
11.2.2.2. Menveo
11.2.2.3. NeisVac-C
11.2.2.4. Nimenrix
11.2.2.5. Others
11.2.3. Combination Vaccines
11.2.3.1. MenHibrix
11.2.3.2. Menitorix
11.2.4. Men B Vaccines
11.2.4.1. Bexsero
11.2.4.2. Trumenba
11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Others (online pharmacies, drug stores)
11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Meningococcal Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
12.2.1. Polysaccharide
12.2.1.1. Menomune
12.2.1.2. Mencevax
12.2.1.3. NmVac4
12.2.1.4. Others
12.2.2. Conjugate Vaccines
12.2.2.1. Menactra
12.2.2.2. Menveo
12.2.2.3. NeisVac-C
12.2.2.4. Nimenrix
12.2.2.5. Others
12.2.3. Combination Vaccines
12.2.3.1. MenHibrix
12.2.3.2. Menitorix
12.2.4. Men B Vaccines
12.2.4.1. Bexsero
12.2.4.2. Trumenba
12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Others (online pharmacies, drug stores)
12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
13.2.1. Polysaccharide
13.2.1.1. Menomune
13.2.1.2. Mencevax
13.2.1.3. NmVac4
13.2.1.4. Others
13.2.2. Conjugate Vaccines
13.2.2.1. Menactra
13.2.2.2. Menveo
13.2.2.3. NeisVac-C
13.2.2.4. Nimenrix
13.2.2.5. Others
13.2.3. Combination Vaccines
13.2.3.1. MenHibrix
13.2.3.2. Menitorix
13.2.4. Men B Vaccines
13.2.4.1. Bexsero
13.2.4.2. Trumenba
13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Others (online pharmacies, drug stores)
13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Sanofi SA
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Novartis International
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Nuron Biotech.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. JN-International Medical Corporation.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Serum Institute of India Ltd
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Baxter International
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us